NCT02586103已完成不适用
Prospective Study Assessing the Validity of Y-PAS (Yale Preoperative Anxiety Scale) to Predict Patients Undergoing Magnetic Resonance Imaging Without the Use of Sedation/General Anesthesia
Arlyne Thung1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2015年11月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Anxiety score
研究概览
简要总结
The mYPAS (Modified Yale Preoperative Anxiety Scale) is a quick, easy, validated and "gold standard" assessment tool to measure pediatric anxiety in the perioperative period. Therefore the objective of the current prospective study is examine if the mY-PAS is an effective screening tool to differentiate patients who would succeed versus fail for MRI without sedation/anesthesia.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •all patients and parents who are willing to participate in the simulated practice MRI on the day of or prior to their scheduled MRI.
排除标准
- •patients/parents who refuse to go through the practice MRI sessions.
结局指标
主要结局
Anxiety score
时间窗: Immediately following MRI simulation
Modified Yale Preoperative Anxiety Scale
次要结局
未报告次要终点
研究者
Arlyne Thung
Clinical Assistant Professor
Nationwide Children's Hospital
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Comparing Virtual Reality (VR) to Non-VR for Decreasing Preoperative/Procedural AnxietyPreoperative AnxietyNCT05094141University of Texas Southwestern Medical Center89
已完成
不适用
Youth understanding of questions that measure anxiety and stressHealthy children- YAM-5 questionnaire- PeSSKi questionnaire- Migrant childrenTCTR20230503002niversity of Oxford10
已完成
不适用
Preoperative Anxiety During COVID-19Pandemic, COVID-19AnxietyNCT05114967University of Thessaly116
尚未招募
不适用
The Evaluation of a Preanaesthesia Assessment ClinicPreoperative Anaesthesia ClinicCancellation RateIntraoperative EventsColon DiseaseNCT05520229University of Agder2,600
招募中
不适用
Special Drug Use-results Surveillance of Tafinlar/MekinistBRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid TumorNCT06262919Novartis Pharmaceuticals110